EUCTR2007-002557-23-FR进行中（未招募）不适用
A Phase I/II Open-Label Dose Escalation Study to Investigate the Safety and Tolerability of Acadesine in Patients with B-Cell Chronic Lymphocytic Leukaemia
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •B-CLL patients with refractory or relapsed disease who have received either a fludarabine containing treatment regimen or an alkylating agent.
- •Diagnosis of B-CLL according to NCI Working Group Criteria.
- •Have an elevated B-cell count of = 5000/mm3.
- •Have a T-cell count = 200/mm3.
- •ECOG Performance Status < 2.
- •Have a life expectancy of at least 3 months.
- •Age > 18 years, of either gender.
- •Have given written informed consent, prior to any study related procedure not part of the patient’s normal medical care.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients who, in the opinion of the Investigator, need immediate treatment with proven chemotherapy and/or immunotherapy, and/or transplantation.
- •Have B-CLL with central nervous system involvement.
- •Have participated in any other investigational drug study or have undergone an experimental therapeutic procedure considered to potentially interfere with the study in the 30 days preceding Day 1.
- •Have received chemotherapy or radiotherapy treatment in the 30 days preceding Day 1.
- •Require use of drugs or substances which inhibit platelet aggregation during the 30 days prior to Day 1 or during the study. These include: ADP receptor inhibitors (ticlopidine, clopidogrel), aspirin and other NSAIDs including COX inhibitors (except COX-2-selective inhibitors), dipyridamole, phosphodiesterase inhibitors (cilostazol), calcium channel blockers such as nifedipine, xanthines (eg theophylline, aminophylline) and substances containing caffeine. Glycoprotein IIB/IIIA inhibitors, including abciximab, eptifibatide and tirofiban, are also contraindicated.
- •Require oral or parenteral steroids with the exception of inhaled steroids or low-dose oral steroids (<10mg prednisolone per day or equivalent) for an indication other than B-CLL.
- •Have a serious medical or psychiatric condition that could, in the Investigator’s opinion, potentially interfere with their treatment and/or participation in the study.
- •Have uncontrolled diabetes mellitus that requires insulin treatment or is not controlled on oral therapy.
- •Have a history of gout.
- •Have a serious concomitant disease including:
- •oSignificant cardiac disease - New York Heart Association Classes III or IV or have suffered a myocardial infarction in the last 6 months.
- •oChronic pulmonary obstructive disease with hypoxemia.
- •oClinically active auto-immune disease.
- •oActive infection such as tuberculosis, CMV (Cytomegalovirus).
- •Any secondary malignancy requiring active treatment (except hormonal therapy).
- •Have inadequate bone marrow reserve: neutrophils < 1.0 x 109/L, platelet count < 50 x 109/L (unsupported by transfusion), or coagulation abnormalities.
- •Have inadequate liver function: total bilirubin > 1.5 x upper limit of normal values (ULN), AST, ALT, or alkaline phosphatase > 2.5 x ULN.
- •Have inadequate renal function, defined by serum creatinine = 1.5 x ULN, unless creatinine clearance is measured and found to be at least 90 mL/min.
- •Have serum uric acid levels outside the normal range.
- •Females of childbearing potential who are unwilling to employ adequate means of contraception (hormonal contraceptive, intrauterine device, diaphragm with spermicide or condom with spermicide) for the duration of the study and 30 days after the last acadesine administration.
- •Pregnant or lactating females.
- •Male patients who are not surgically sterile and who are unwilling to use a condom with spermicide for the duration of the study and for 3 months after the last acadesine administration.
- •Abuse of alcohol or other recreational drugs.
- •Known HIV or Hepatitis B (unless clearly due to vaccination) or C positive.
- •Known allergy to acadesine or any of its excipients.
- •Have undergone previous allogeneic stem cell transplant.
- •Transformation to Richter’s syndrome or other aggressive B-cell malignancy.
研究者
相似试验
进行中（未招募）
不适用
A Phase I/II Open-Label Dose Escalation Study to Investigate the Safety and Tolerability of Acadesine in Patients with B-Cell Chronic Lymphocytic LeukaemiaEUCTR2007-002557-23-BEAdvancell Advanced In Vitro Cell Technologies, S.A40
尚未招募
2 期
A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects with NUT Midline Carcinoma (NMC) and Other Cancers (BET115521)NUT Midline Carcinoma and other solid tumors10027655NL-OMON43804GlaxoSmithKline10
进行中（未招募）
不适用
A Phase I/IIa Open-label Dose Escalation Study to Assess the Safety, Tolerability and Preliminary Efficacy of AT9283 in Patients with Intermediate or High-Risk Myelofibrosis.MedDRA version: 9.1Level: LLTClassification code 10028537Term: MyelofibrosisMyelofibrosisEUCTR2007-005299-15-GBAstex Therapeutics Ltd
未知
1 期
A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in JapaAdvanced Solid TumorJPRN-jRCT2080220419AstraZeneca
进行中（未招募）
1 期
A non-blinded Phase I/II study that evaluates the safety and tolerability of increasing doses of the study drug GDC-0032 administered to patients for the treatment of advanced cancers and in combination with endocrine therapy for the treatment of hormone receptor-positive breast cancerPatients with locally advanced or metastatic solid tumors and in combination with endocrine therapy in patients with locally advanced or metastatic hormone receptor-positive breast cancerMedDRA version: 17.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864EUCTR2012-002042-21-FRGenentech, Inc.392